Cybin Inc Stock Price, News & Analysis

Cybin Inc. (AMEX:CYBN) announced a significant milestone with a confirmed scientific advice meeting scheduled with the UK Medical and Healthcare Products Regulatory Agency (MHRA) for Q1 2022. This meeting is a key step towards advancing its lead investigational candidate, CYB003, into clinical development, targeting major depressive disorder (MDD) and alcohol use disorder (AUD). Encouraging preclinical results indicate CYB003’s advantages over oral psilocybin, including reduced dose variability, faster onset, and improved brain penetration. A clinical trial application is expected to be filed with the MHRA in Q2 2022.

Cybin, a biopharmaceutical company focused on developing therapeutics from psychedelics, has announced that CEO Doug Drysdale will present at the Stifel GMP 2nd Annual Future of Healthcare Conference.

The event will be held virtually on December 8, 2021, at 3:30 p.m. ET. Interested parties can register and view the presentation via webcast. Cybin aims to create innovative solutions for mental health issues by leveraging proprietary drug discovery platforms and collaborations with leading scientists.

Cybin Inc. has received FDA authorization for a Phase 2 clinical trial focusing on psychedelic-assisted psychotherapy with psilocybin for healthcare workers affected by COVID-related distress. Conducted at the University of Washington under Dr. Anthony Back, the trial aims to treat depression, anxiety, and burnout among frontline clinicians. This study builds on the EMBARK model designed to customize therapy for diverse clinical populations. Cybin's leadership emphasizes the potential of psychedelics to enhance mental health amid ongoing pandemic pressures.

Cybin is set to participate in the 2nd Annual H.C. Wainwright Psychedelics Conference on December 6, 2021. CEO Doug Drysdale will engage in a fireside chat available on demand starting at 7:00 a.m. ET. Interested listeners can access the chat and the archived webcast through Cybin's investor relations website. Founded in 2019 and headquartered in Canada, Cybin focuses on developing safe therapeutics to address mental health issues using its unique drug discovery platforms.

Cybin Inc. has announced that its subsidiary, Adelia Therapeutics, has successfully achieved milestones outlined in a December 2020 agreement. This includes the issuance of 31,721.5 Class B common shares worth approximately $628,879.34 to Adelia shareholders at an effective price of $1.98 per share. These Class B shares are exchangeable for Cybin shares at a ratio of 10 to 1, with specific exchange conditions. Cybin continues to advance its mission to develop therapeutics addressing mental health issues through innovative drug delivery systems.

Cybin, a biopharmaceutical company, has announced a grant for the establishment of a pioneering psychedelic treatment clinic at Lenox Hill Hospital in New York. This initiative will focus on aiding marginalized communities by offering treatment at no out-of-pocket cost. The clinic aims to provide psychedelic therapies for severe mental health conditions and frontline workers affected by COVID-19. Clinicians will be trained in various psychedelic-assisted psychotherapies, underlining the potential of these modalities in treating previously intractable conditions like depression and PTSD.

Cybin Inc. reported its unaudited financial results for the second quarter ended September 30, 2021. The company holds C$75.2 million in cash, but recorded a net loss of C$17.6 million. Cybin is advancing its CYB003 program, aiming for an investigational new drug application submission in Q2 2022 for treating depression and addiction. Recent highlights include a Schedule I manufacturing license, FDA approval for a feasibility study with Kernel Flow technology, and the launch of the EMBARK program for frontline workers.

Cybin, a biopharmaceutical company focused on advancing Psychedelics to Therapeutics, announced that CEO Doug Drysdale will present at the Jefferies London Healthcare Conference from November 18-19, 2021. The presentation will be available on demand starting November 18 at 8:00 AM GMT until November 19 at 5:00 PM GMT. Investors can access the webcast through Cybin's website. Founded in 2019 and headquartered in Canada, Cybin collaborates with leading partners to develop therapeutics for mental health issues.

Cybin Inc. (NYSE American:CYBN) will report its financial results for Q2 fiscal 2021, ending September 30, 2021, on November 15, 2021. A conference call to discuss results will occur on the same day at 4:30 p.m. EST, hosted by CEO Doug Drysdale. The company is dedicated to developing safe and effective psychedelic therapeutics for mental health. Cybin operates in Canada, the U.S., the UK, and Ireland, leveraging advanced drug discovery and delivery systems.